NYSE:MYOV

Myovant Sciences Stock Forecast, Price & News

$21.97
-0.86 (-3.77 %)
(As of 09/20/2021 12:54 PM ET)
Add
Compare
Today's Range
$21.78
$22.38
50-Day Range
$18.94
$26.99
52-Week Range
$13.42
$30.90
Volume3,826 shs
Average Volume813,907 shs
Market Capitalization$2.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.87
30 days | 90 days | 365 days | Advanced Chart
Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.


Myovant Sciences logo

About Myovant Sciences

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

784th out of 1,352 stocks

Pharmaceutical Preparations Industry

384th out of 665 stocks

Analyst Opinion: 2.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

Is Myovant Sciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Myovant Sciences stock.
View analyst ratings for Myovant Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Myovant Sciences?

Wall Street analysts have given Myovant Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Myovant Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Myovant Sciences
.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) posted its quarterly earnings results on Wednesday, July, 28th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.46. The business earned $41.06 million during the quarter, compared to analyst estimates of $61.19 million.
View Myovant Sciences' earnings history
.

How has Myovant Sciences' stock price been impacted by Coronavirus (COVID-19)?

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MYOV shares have increased by 153.7% and is now trading at $22.07.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MYOV?

6 equities research analysts have issued 1-year price objectives for Myovant Sciences' shares. Their forecasts range from $18.00 to $32.00. On average, they expect Myovant Sciences' share price to reach $25.60 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts' price targets for Myovant Sciences
or view top-rated stocks among Wall Street analysts.

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the following people:
  • David C. Marek, Chief Executive Officer & Director
  • Jeffrey D. Nornhold, Senior VP-Pharmaceutical Operations & Development
  • Juan Camilo Arjona Ferreira, Chief Medical Officer
  • Matthew Lang, Secretary, Chief Administrative & Legal Officer (LinkedIn Profile)
  • Lauren Merendino, Chief Commercial Officer

Who are some of Myovant Sciences' key competitors?

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bellevue Group AG (5.72%), State Street Corp (2.49%), PFM Health Sciences LP (2.08%), BlackRock Inc. (1.15%), Vanguard Group Inc. (0.84%) and Lord Abbett & CO. LLC (0.58%). Company insiders that own Myovant Sciences stock include Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, Matthew Lang and Sciences Ltd Roivant.
View institutional ownership trends for Myovant Sciences
.

Which institutional investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pier Capital LLC, Goldman Sachs Group Inc., PFM Health Sciences LP, FMR LLC, Group One Trading L.P., Bank of New York Mellon Corp, and Blackcrane Capital LLC. Company insiders that have sold Myovant Sciences company stock in the last year include Ferreira Juan Camilo Arjona, Frank Karbe, and Matthew Lang.
View insider buying and selling activity for Myovant Sciences
or view top insider-selling stocks.

Which institutional investors are buying Myovant Sciences stock?

MYOV stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Millennium Management LLC, Laurion Capital Management LP, Marshall Wace North America L.P., Citigroup Inc., Blueshift Asset Management LLC, and Point72 Asset Management L.P.. Company insiders that have bought Myovant Sciences stock in the last two years include Chemical Co Ltd Sumitomo, and Sciences Ltd Roivant.
View insider buying and selling activity for Myovant Sciences
or or view top insider-buying stocks.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $22.07.

How much money does Myovant Sciences make?

Myovant Sciences has a market capitalization of $2.03 billion and generates $59.32 million in revenue each year. The company earns $-255,130,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Myovant Sciences have?

Myovant Sciences employs 407 workers across the globe.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is www.myovant.com.

Where are Myovant Sciences' headquarters?

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 442074003351 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.